These results suggest that chronic treatments of CRF-R1 antagonists (at doses for which acute administration is effective to inhibit ACTH release) would neither hamper HPA axis activity nor induce adrenal insufficiency in non-stressed conditions. The gene discussed is POMC; the disease is Adrenal insufficiency.